Maha Hadi Hussain, M.D.

Clinical Professor, Department of Internal Medicine

Dr. Maha Hussain's research efforts are focused on the development of new
therapies for patients with genitourinary malignancies particularly bladder and
prostate cancer. She serves as principal investigator of multiple ongoing clinical
trials which test the efficacy of intermittent androgen deprivation in patients with
stage D2 prostate cancer (a phase III international trial sponsored by SWOG); a multi-center phase II evaluation of Herceptin, Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced urothelial cancer (sponsored by CTEP); a
phase II trial of epothilon B analogue administered every 21 days in patients with
hormone-refractory prostate cancer (sponsored by SWOG); an evaluation of
weekly Docetaxel and Capecitabine in the treatment of advanced urothelial cancer
(a multi-center clinical trial); an assessment of the utility of primary
chemotherapy with Docetaxel plus Capecitabine in selected patients with newly
diagnosed localized or locally advanced prostate cancer (a multicenter clinical
trial).

Hussain M, Smith DC, El-Rayes BF, Du W, Vaishampayan U, Fontana Joseph, Sakr W, Wood D: Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer. Urology 61:774-780, 2003.

Tangen CM, Faulkner JR, Crawford ED, Hirano D, Thompson IM, Eisenberger M, Hussain M: Ten-years survival in patients with metastatic prostate cancer. Clinical Prostate Cancer, (1):41-45, 2003.

Hussain M, Vaishampayan U, Heilbrun L K, Jain V, LoRusso P M, Ivy P, Flaherty L: A Phase II Study of Rebeccamycin Analog (NSC655649) in Metastatic Renal Cell Cancer. Investigational New Drugs 21:465-471, 2003.

Barnholtz-Sloan JS, Severson RK, Vaishampayan U, Hussain M. Survival analysis of distant prostate cancer by decade (1973-1998) in the Detroit Metropolitan Surveillance, Epidemiology and End Results (SEER) program registry: Has surveillance improved? Cancer Causes and Control, 14:681-685, 2003.

Vaishampayan U, Do H, Hussain M, Schwartz K: Racial disparity in incidence patterns and outcome of kidney cancer. Urology 62, 1012-1017, 2003.

Hussain M, Sarkar FH, Djuric Z, Pollak MN, Banerjee M, Doerge D, Fontana J, Chinni S, Davis J, Forman J, Wood DP, Kucuk O: Soy isoflavones modulate serum PSA level in patients with prostate cancer. Nutrition and Cancer, 47, 2:111-117, 2003.

Vaishampayan U, Fontana J, Du W and Hussain M: An active oral regimen of estramustine and etoposide in newly diagnosed metastatic prostate carcinoma. Am J Oncol (In press), 2004.

Li Y, Li X, Hussain M, Sarkar F: Regulation of microtubule, apoptosis and cell cycle related genes by taxotere in prostate cancer cells analyzed by microarray. Neoplasia 6,1, 2004 (In press).

Hong X, Li Y, Hussain M, Sarkar FH: Gene expression profiling reveals novel targets of estramustine phosphate in prostate cancer cells. Cancer Letters (In press) 2004.